CoChat

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

Open access
Krupp, L.B., Christodoulou, C., Melville, P., Scherl, W.F., Pai, L.-Y., Muenz, L.R., He, D., Benedict, R.H.B., Goodman, A., Rizvi, S., Schwid, S.R., Weinstock-Guttman, B., Westervelt, H.J., Wishart, H. · 2011 · Neurology
Cited by 115

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: The goal of this study was to determine if memory would be improved by donepezil as compared to placebo in a multicenter, double-blind, randomized clinical trial (RCT). METHODS: Donepezil 10 mg daily was compared to placebo to treat memory impairment. Eligibility criteria included the following: age 18-59 years, clinically definite multiple sclerosis (MS), and performance ≤ ½ SD below published norms on the Rey Auditory Verbal Learning Test (RAVLT). Neuropsychological assessments were performed at baseline and 24 weeks. Primary outcomes were change on the Selective Reminding Test (SRT) of verbal memory and the participant's impression of memory change. Secondary outcomes included changes on other neuropsychological tests and the evaluating clinician's impression of memory change. RESULTS: A total of 120 participants were enrolled and randomized to either donepezil or placebo. No significant treatment effects were found between groups on either primary outcome of memory or any secondary cognitive outcomes. A trend was noted for the clinician's impression of memory change in favor of donepezil (37.7%) vs placebo (23.7%) (p = 0.097). No serious or unanticipated adverse events attributed to study medication developed. CONCLUSIONS: Donepezil did not improve memory as compared to placebo on either of the primary outcomes in this study. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence which does not support the hypothesis that 10 mg of donepezil daily for 24 weeks is superior to placebo in improving cognition as measured by the SRT in people with MS whose baseline RAVLT score was 0.5 SD or more below average.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e318218107a

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 115

Metadata

Authors
Krupp, L. B., Christodoulou, C., Melville, P., Scherl, W. F., Pai, L.-Y., Muenz, L. R., He, D., Benedict, R. H. B., Goodman, A., Rizvi, S., Schwid, S. R., Weinstock-Guttman, B., Westervelt, H. J., & Wishart, H.
Venue
Neurology
Published
2011-04-26
Volume
76
Issue
17
Pages
1500-1507
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W4242280770
Cited by
115
References
5
FWCI
8.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. https://app.cochat.ai/papers/10.1212/wnl.0b013e318218107a
The paper
Krupp, L. B., Christodoulou, C., Melville, P., Scherl, W. F., Pai, L.-Y., Muenz, L. R., He, D., Benedict, R. H. B., Goodman, A., Rizvi, S., Schwid, S. R., Weinstock-Guttman, B., Westervelt, H. J., & Wishart, H. (2011). Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. https://doi.org/10.1212/wnl.0b013e318218107a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.